TherapeuticsMD
TXMD
144 hedge funds and large institutions have $982M invested in TherapeuticsMD in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 20 closing their positions.
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
13% more capital invested
Capital invested by funds: $867M → $982M (+$115M)
7% more funds holding
Funds holding: 134 → 144 (+10)
0.02% less ownership
Funds ownership: 1.52% → 1.5% (-0.02%)
63% less call options, than puts
Call options by funds: $2.71M | Put options by funds: $7.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.4M |
| 2 |
Bank of New York Mellon
New York
|
+$17.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.98M |
| 4 |
First Eagle Investment Management
New York
|
+$8.73M |
| 5 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.1M |
| 2 |
JP Morgan Chase
New York
|
-$13.3M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$12.4M |
| 4 |
CCI
Columbus Circle Investors
|
-$10.7M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$3.49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
151
Virtu Financial
New York
| – | -$365K | -1,381 | Closed |
|
|
LCM
152
Landscape Capital Management
Englewood,
New Jersey
| – | -$259K | -978 | Closed |
|
|
HIH
153
HRS Investment Holdings
New York
| – | -$224K | -847 | Closed |
|
|
TRCT
154
Tower Research Capital (TRC)
New York
| – | -$193K | -730 | Closed |
|
|
QT
155
Quantbot Technologies
New York
| – | -$189K | -716 | Closed |
|
|
OAC
156
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$185K | -698 | Closed |
|
157
Squarepoint
New York
| – | -$120K | -454 | Closed |
|
158
HighTower Advisors
Chicago,
Illinois
| – | -$111K | -418 | Closed |
|
|
N
159
Natixis
Paris,
France
| – | -$103K | -389 | Closed |
|
|
BCM
160
BlueCrest Capital Management
St Helier,
Jersey
| – | -$77K | -292 | Closed |
|
|
AP
161
AHL Partners
London,
United Kingdom
| – | -$62K | -234 | Closed |
|
|
DTL
162
Dynamic Technology Lab
Singapore
| – | -$62K | -232 | Closed |
|
|
CSS
163
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$55K | -207 | Closed |
|
164
Simplex Trading
Chicago,
Illinois
| – | -$47.9K | -172 | Closed |
|
TXMD Hedge Fund Activity: Q4 2017 in Review
144 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2017, worth a combined $982M — up 13% from $867M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TXMD positions and 20 closed out — a net gain of 11 holders — while 49 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock, adding an estimated $18.4M. The largest seller was Fidelity Investments, cutting an estimated $34.1M.
- 144 institutional investors held TherapeuticsMD (TXMD) as of Q4 2017, up from 134 in Q3 2017.
- Funds reported $982M of TherapeuticsMD stock for Q4 2017, up 13% quarter-over-quarter.
- 31 funds opened new TherapeuticsMD positions in Q4 2017 and 20 closed out, a net change of +11 holders.
- The largest TherapeuticsMD buyer in Q4 2017 was BlackRock, an estimated $18.4M added.
- The largest TherapeuticsMD seller in Q4 2017 was Fidelity Investments, an estimated $34.1M sold.
Based on aggregated 13F filings for Q4 2017.